| 摘要 |
Disclosed is the use of nicotine receptor agonists, particularly dimethylphenylpiperazinium or DMPP , for treating inflammatory diseases, including a variety of pulmonary diseases. Such agonists have fewer side effects than other anti-inflammatory drugs, such as steroids. Moreover, these agonists can be used alone or in combination with other anti-inflammatory drugs to alleviate pulmonary diseases. Specific diseases include asthma , chronic obstructive pulmonary disease ( COPD ), interstitial pulmonary fibrosis ( IPF ), sarcoidosis , Hypersensitivity pneumonitis ( HP ), and Bronchitis obliterans with organizing pneumonitis ( BOOP ).
|
